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Summary
Background: Endovascular aneurysm repair (EVAR) 
(using an Federal Drug Association-approved AneuRx® 
device) compared to conventional surgical repair of 
abdom inal aortic aneurysm (AAA) previously rendered 
favourable outcomes regarding post-operative pain, 
avoidence of laparotomy, and rapid rehabilitation and 
hospital discharge in high-risk patients, including octage-
narians.
Objectives: To assess the safety, reduction in aneurysm-
related deaths, and interim survival data up to 72 
months after AAA exclusion by endoluminal endografts 
(EVAR).
Design: We carried out an open, controlled, prospective, 
multidisciplinary EVAR study for the period 1998 to 
2003 (six years). In the earlier part of the study, EVAR 
was compared with previously published results of 
conventional open aneurysmectomy surgery.
Setting: Heart Unit, Panorama Medi-Clinic, Parow, 
South Africa.
Participants: We recruited adult male and female patients 
presenting with AAA and fulfilling the inclusion criteria 
for endovascular repair, as recommended by the consen-
sus 2003 meeting of the Vascular Association of South 
Africa (VASSA). All patients were offered open surgery 
as an alternative and were entered into the VASSA 
EVAR trial registry. Pre-operatively, AAA anatomy was 
assessed by spiral-computed tomography (CT), and 
selectively with conventional angiography and intravas-
cular ultrasound (IVUS). Informed consent was obtained 
in accordance with the recommendations of the Senate 
of Surgery Paper 2, Ethical Guidelines, Great Britain 
and Ireland. Patients underwent EVAR by a multidisci-
plinary interventional team.
Interventions: Two hundred and seven adult patients 
with AAA were assessed. Forty-four of the 207 (21.2%) 
were excluded from EVAR because of irreversible co-
morbid factors and complex aneurysm morphology. One 
hundred and sixty-three patients (78%), with a mean 
age of 70.7 years (range 60−91 years), underwent EVAR 
(1998−2003). Five patients were lost to follow-up (3%). 
Median AAA diameter was 56.9 mm and ASA ratings 
were I, 1.2%; II, 15.9%; III, 57%; IV, 22.6%; and 
V, 2.4%. EVAR was performed in high- and low-risk 
categories of both sexes. Most patients were in ASA 
groups III and IV.
Devices deployed: EVAR was performed using a selection 
of endografts over 72 months − AneuRx® (Medtronic) 
47; Talent® (Medtronic) 49; Vanguard® three; Zenith® 
(Cook) one; Powerlink® (Endologix) 62; and other, one. 
Results: Thirty-day outcome: successful deployment 
99%, primary stent patency 97%, surgical conversion 
0.6%, procedural or intra-operative mortality 1.2%, 
30-day mortality 4.3%, endoleaks 1.84%, and secondary 
intraprocedural endovascular interventions 24.5%. Peri-
operative mortality was 3.1% (one aneurysm related). 
One patient had suspected endograft infection. Late 
mortality was 21.4% (35 patients due to co-morbidities, 
and one was aneurysm related). Follow-up was a median 
of 28.3 months (range 1−69 months). In 163 patients, two 
persisting endoleaks (1.2%) were detected. Endotension 
was detected in 3/163 (1.8%) with average sac increase 
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of 0.8 cm. Conversion to open surgery was needed in one 
patient (0.6%). Co-morbidities that contributed to late 
mortality included multi-organ failure, ischaemic heart 
disease (IHD), cardiomyopathy, renal failure, stroke and 
cancer. One procedural rupture was fatal (0.6%). Two 
late ruptures occurred; one was successfully endostented 
and the other patient died after a failed surgical interven-
tion (0.6%). 
Endovascular repair of AAA is more expensive than 
conventional surgery. Introduction of the Endologix stent 
has reduced operative time from 120 to 60 minutes in 
un complicated patients. Newer-generation aortic stents 
allow better control of negative remodeling and stent 
migration.
Conclusion: A multidisciplinary team can safely perform 
EVAR, with a low 30-day mortality rate in selected 
patients graded ASA II−IV and with favourable aortic 
aneurysm morphology. About 22% of patients with 
AAA are not suited for EVAR. Persisting late endoleaks 
occurred in 1.2% of the cohort study and were not device 
specific. Life-long follow-up post EVAR is a prerequisite 
to detect late device failure, endoleaks and aneurysm-sac 
enlargement, and to assure the durability of these mid-
term results. Short-term aneurysm rupture prevention 
is a predictable outcome in high-risk groups.
Cardiovasc J South Afr 2005; 16: 36–47. www.cvjsa.co.za
The clinical consequence of an abdominal aortic aneurysm 
(AAA) includes unpredictable rupture into the peritoneal or 
retroperitoneal space with potentially massive, fatal haemor-
rhage.1 The purpose of elective prosthetic engraftment for 
large aneurysms is primarily to prevent aneurysm rupture 
(aneurysm-related death) and exsanguination.1-13 A partial 
solution to this potentially deadly and preventable complica-
tion of AAA is to identify susceptible individuals and to 
exclude the aneurysm before unpredictable rupture occurs.1-3 
This is a hotly debated subject5 and recently, selection of 
patients for conventional surgery or endovascular aneurysm 
repair (EVAR) based on risk for rupture has been ques-
tioned.3,5 Long-term studies confirm that surgically treated 
patients with AAA, despite the advent of EVAR, experi-
ence a good quality of life and can enjoy a normal 
lifespan.6-10 Recent studies, however, suggest that EVAR 
could potentially replace open surgery in the treatment of 
AAA in about 75% of referred cases.11-15,16-29
Despite risk-factor determination, conventional surgical 
repair of AAA is unquestionably associated with unexpected 
peri- and post-operative morbidity, such as myocardial 
infarction, multiple organ failure, respiratory and renal 
failure, stroke, and graft sepsis.5-9,11-13 Our own cardiological 
experience indicates that 60% of persons undergoing AAA 
repair, by whatever route, have established coronary artery 
disease.4 Mortality of elective surgery could well be closer 
to 8% in higher-risk groups.4 Although the surgical outcome 
after conventional repair of AAA is well documented, about 
10% of patients develop significant elongation and dilatation 
at the graft/vessel interface.5 Eastcott, Sheil and co-workers 
commented that late failure at this point was an important 
cause of aneurysm-related death in long-term follow-up 
studies after conventional surgery.14,15 Aneurysm-related 
death due to rupture is therefore also not completely 
abrogated by conventional open surgery.14-16
With modern advances in endoluminal techiques, elective 
AAA repair can be accomplished effectively and safely with 
minimal invasive EVAR, provided patient selection and 
aneurysm anatomy is optimal, expertise and training appro-
priate, and the necessary infrastructure, back-up intensive-
care facilities and anaesthesia support are available.17-33
EVAR has evolved from an experimental technique to an 
evidence-based procedure in specialised centres.23-35 Open 
surgery still remains a viable option if aneurysm anatomy 
is unfavorable.6-10 The current series has been supported by 
extensive prior cadaveric laboratory studies performed at the 
Faculty of Health Sciences, University of Stellenbosch.16,31 In 
most studies, EVAR has been applied in patients with pro-
hibitive risks, who were refused anaesthesia for traditional 
surgery or were identified as ‘unfit’ for surgery.28
Recently, centres of excellence have documented clinical 
experience and learning curves since the pioneering work 
of Parodi, with reference to the application of minimally 
invasive EVAR.12,36-45 Encouraging short-, intermediate- and 
late-outcome results are predictable after EVAR.24-26,45 EVAR 
has been applied in low- and high-risk patients with 
AAA.18,19,28 There are no 10-year reported follow-up studies 
at present. General guidelines have been suggested for 
training and for the application of EVAR of AAA in 
clinical practice.32,46 In most countries, interventionalists are 
encouraged to document their patients with EVAR registries, 
thereby facilitating audit and peer review.12,46 
This study describes a multidisciplinary team’s interim 
72-month experience using EVAR in the elective treatment of 
selected low- and high-risk patients with AAA at Panorama 
Medi-Clinic over a six-year period (1998–2003). Evaluation 
included outcome-based assessment regarding technical 
problems, complications, survival, endoleaks, late rupture, 
device failure, device-related death, aneurysm-related death, 
morbidity and mortality in 163 patients undergoing consecu-
tive EVAR.
Materials and Methods
Referred patients with abdominal aneurysms were selected 
for EVAR according to a recognised protocol and guide-
lines.10,23,33 Assessment was performed by a multidiscipli-
nary interventional team consisting of surgeons, vascular 
surgeons, radiologists and an interventional cardiologist. All 
patients were counseled, and signed informed consent.47 The 
feasibility of the procedure, risks, treatment options (includ-
ing conventional surgery), and the chance of conversion to 
an open procedure, or the need for secondary interventions 
were explained to recipients. Patients were entered into the 
VASSA EVAR registry.
Inclusion criteria for EVAR10,23,34,35,48-50
Inclusion criteria were as follows: (i) asymptomatic and 
symptomatic abdominal aortic aneurysm more than 50 mm 
in diameter or enlargement of an aneurysm on ultrasound or 
computed tomography (CT) scan; (ii) patent iliac and femo-
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ral arteries that permitted remote endovascular access; (iii) 
a non-aneurysmal proximal aortic neck diameter measuring 
between 18 and 26 mm on pre-operative spiral CT scan; 
(iv) a neck length of 12 mm aorta immediately inferior to 
the lowest renal ostium; this had to be adapted as the renal 
arteries often did not come off parallel;31 (v) patient prepared 
to be followed up at six-monthly intervals, indefinitely; (vi) 
adequate iliac landing zone (proximal to the internal iliac 
artery) with a diameter of 15 mm or more; (vii) concomitant 
AAA and potentially reconstructable peripheral vascular 
occlusive disease (PVD); and (viii) saccular aneurysms, 
anastomotic aneurysms and iliac aneurysms.
Exclusion criteria for EVAR
Exclusion criteria were: (i) frank rupture or inflammatory 
aneurysm; (ii) suprarenal extension of AAA: aortic neck 
length less than 12 mm with severe angulation; (iii) underly-
ing connective tissue disorders (e.g. Marfan’s syndrome); 
(iv) coagulation disorder (i.e. hypercoagulability); (v) renal 
insufficiency; (vi) underlying systemic infection: moribund 
patients; (vii) suspected mycotic aneurysm; (vii) patients 
with an estimated life expectancy of less than one year; 
(ix) bedridden patients and candidates with underlying 
cancer or previous stroke; (x) patients unwilling or unable to 
return for follow-up; (xi) extensive iliac calcification, 
splaying or tortuosity precluding limb access, or engraft-
ment proximal to the internal iliac artery (one patent 
hypogastric was always retained); and (xii) PVD associated 
with gangrenous lesions (i.e. critical ischaemia), incapaci-
tating, multilevel distal disease, or severe distal run-off 
problems.
Evolution of special investigations prior to EVAR
Pre-endostent work-up was as follows: (i) history, clinical 
examination and documentation of risk factors, including 
co-morbidities;4,48-52 (ii) detection of other features of PVD, 
i.e. peripheral aneurysms, occlusive disease and carotid 
bruits; (iii) aneurysm morphological classification based on 
spiral CT (types I, II, III); (iv) ankle brachial index (ABI); 
(v) biochemical baseline tests: full blood count (FBC) and 
erythrocyte sedimentation rate/C-reactive protein, clotting 
profile, electrolytes and urea, plasma glucose, creatinine, 
and liver function tests; (vi) chest X-ray, ECG; (vii) 
cardiological assessement and lung function tests in selected 
patients, to rule out IHD, arrythmias, aortic stenosis and 
cardiomyopathy; and (viii) spiral CT (with contrast enhance-
ment) including three-dimensional views superior and infe-
rior to the AAA, together with characterisation of the iliacs.51 
Features recorded included aneurysm neck diameter, length 
and angulation, flow channels, origins of the renal ostia, 
patency of the inferior mesenteric artery (IMA) and lumbar 
arteries, presence of large collaterals between the superior 
mesenteric artery (SMA) and IMA, wall calcification and 
size of thrombus, degree and extent of iliac tortuosity, 
calcification, occlusion or stenosis thereof. Three-millimetre 
sections were taken from the SMA to the superficial femoral 
artery, allowing definition of important proximal and distal 
delivery target areas. Transaxial scans and angiograms 
were considered the reference standard; (ix) peripheral angio-
grams were selectively performed if poor run-off, multilevel 
disease was anticipated; (x) risk classification (grades I−V) 
according to the American Society of Anaesthesiologists 
(ASA);49 (xi) identification of symptomatic concomitant 
vascular lesions (stenotic or occlusive disease, i.e. coro-
nary, carotid, renal, PVD requiring potential intra- or pre-
operative concurrent interventional treatment; (xii) coronary 
angiography in selected patients; and (xiii) ventricular 
ejection fraction in selected patients.
Assessment prior to discharge
This involved: (i) clinical examination, including abdominal 
palpation, inspection of the femoral arteriotomy site and 
evaluation of the status of peripheral foot pulses; (ii) ABI 
in selected patients; (iii) other procedures deemed necessary 
if indicated (chest radiograph, abdominal X-ray, ECG, clot-
ting profile, renal function); and (iv) ultrasound to detect 
endoleaks and graft position.
EVAR follow-up protocol32
Patient follow-up was scheduled for one and three months, 
then six-monthly thereafter for a period up to six years or 
longer after EVAR.24 Ongoing evaluation included: (i) physi-
cal examination and evaluation of the status of peripheral 
circulation in the feet; (ii) ABI in selected patients; (iii) 
biochemical tests: FBC, urea and creatinine; (iv) abdominal 
X-ray; and (v) selected spiral CT or colour duplex ultra-
sound to detect proximal and distal paraprosthetic leakage 
(endoleaks and perigraft flow), suprarenal aneurysmal dila-
tation, aneurysm enlargement (endotension), graft migra-
tion, stent fracture and device failure.
Statistical analysis
Non-parametric tests and computer data analysis (Statistica) 
were used to assess significance of difference. Results were 
considered significantly different when p < 0.05. All patient 
data were entered into the VASSA EVAR registry.
Technique of EVAR of AAA16,24,26
EVAR of AAA was performed by a multidisciplinary team 
in a fully equipped cardiac catherisation laboratory, using 
aseptic techniques, with operation theatre back-up in the 
event that conversion to an open procedure was needed. 
Arterial access for endoluminal stent-graft placement was 
provided by a vascular surgeon via common femoral artery 
exposure. Either a unilateral or bilateral femoral arteriotomy 
was used (bilateral for AneuRx®, Talent® devices).21 Access 
for EVAR using the Powerlink® (Endologix) bifurcated 
system was through one surgically exposed femoral (right-
sided) artery and a contralateral percutaneously placed 9-F 
sheath.26 Stent grafts were oversized by 10 to 20% relative 
to diameter measurements taken from CT scans. EVAR 
entailed proximal stent-graft placement in close proximity 
inferior to the lowest renal artery ostia and distal landing 
on both common iliac arteries within 10 and 20 mm of the 
origin of the internal iliac arteries. 
Patients received epidural and light general anaesthesia 
(propofol) and were monitored by an anaesthetist. Intra-
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procedural transfemoral haemodynamic monitoring of the 
aneurysm sac pressure via a 9-F sheath and pigtail catheter 
was used to predict and seal type I proximal and distal 
endoleaks. Selective aneurysmal sac contrast angiography 
was used intraprocedurally to facilitate either thrombin or 
coil embolisation of endoleaks. Immediately before inser-
tion of the prosthesis and after heparisation (5 000 units) 
and triple femoral vessel clamping, a 5- to 7-mm transverse 
arteriotomy was performed in the common femoral arteries 
immediately proximal to the origin of the profunda femoris 
arteries. After stent-graft deployment, completion angio-
graphy was performed to determine the exact position, 
alignment, conformability of the prosthesis, and evidence
of intraprocedural endoleaks. Additional stents or exten-
sions were inserted to control type I endoleaks in 
the theatre. Doppler flow studies were selectively used 
in theatre to assess distal circulation and perfusion. 
Prophylactic antibiotics included one gram of intravenous
cefazolin.
Results
Two hundred and seven patients with AAA were assessed 
over a six-year period. Forty-four (21%) were excluded from 
EVAR due to unfavourable aneurysm morphology, severe 
distal PVD, access problems, calcification, co-morbidities, 
aneurysm neck angulation and severe ischaemic heart 
disease (aortic stenosis, cardiomyopathy). Younger patients 
under 60 years were referred for open conventional surgery. 
During a 72-month period (1998−2003), 163 of 207 patients 
(78%) underwent EVAR by a multidisciplinary team at 
Panorama Medi-Clinic, and data were entered into the 
VASSA EVAR registry. Patient profile and co-morbidities 
after EVAR are reflected in Table I. With regard to costs, in 
uncomplicated cases, open conventional surgery for AAA is 
R20 000 cheaper than the endovascular option.
Patient demographics
There were 150 males and 13 females (p < 0.005). Mean 
age was 70.7 years (range 60 to 91 years). Between 22 
and 34 stents were inserted annually in the six-year period 
(average 27 per annum). ASA classification was as follows: 
I, 1.2%; II, 15.9%; III, 57%; IV, 22.6%; and V, 2.4%. 
Median aneurysm diameter was 56.9 mm. Endograft devi-
ces inserted included: AneuRx® (Medtronic) 47; Talent® 
(Medtronic) 49; Vanguard® three; Zenith® (Cook) one; 
Powerlink® (Endologix) 62; and other, one. 
Procedures and complications 
The outcome of EVAR in 163 patients is tabulated in Table 
II and technical difficulties are reflected in Table III. The 
TABLE II. EVAR IN 163 PATIENTS – DEVICE ENHANCEMENT 
AND 30-DAY OUTCOME.
Variable  Total %
Successful device deployment  162 99
Surgical conversion*  1 0.6
Procedural mortality  2 1.2
30-day mortality rate  7 4.2
Endoleaks  3 1.8
Secondary endovascular interventions 
  (during engraftment)  40 24.5
Endograft sepsis  1 0.6
*Aneurysm rupture one week after EVAR.
TABLE I. CO-MORBIDITIES AND CHARACTERISTICS OF PATIENTS 
UNDERGOING EVAR (60 MONTHS).
Elective 159 96.9%
Ruptured (contained) 4* 2.4%
High-risk patients (ASA grades III−V) 135 82.3%
ASA grade
  I  2 1.2%
  II  26 15.8%
  III  95 57.9%
  IV  37 22.5%
  V  3 1.8%
Risk factors  
TIA/stroke 12 7.3%
CABG 24 14.6%
Ischaemic heart disease 108 65%
Hypertension 68 41.4%
Diabetes mellitus 16 9.7%
Peripheral occlusive disease 33 20%
COPD 22 13.4%
Renal impairment 11 6.7%
Pre-operative dialysis 0 0%
Atrium fibrillation 7 4.2%
Cardiomyopathy 21 12.8%
Pre-operative sizing (mm)  
AAA diameter (range/median) 3.2–9.5 cm   5.6 cm (median)
Aortic neck length  8–7 mm 18.8 mm ( median)
Aortic neck diameter 14–50 mm 17.9 mm (median)
*Patient 64: rupture (pre-procedure); Patient 20: dissection (pre-procedure); Patient 41: rupture 
(during procedure); Patient 109: rupture (at 20 months post-procedure).
TABLE III: TECHNICAL COMPLICATIONS/PROCEDURAL MORBIDITY 
(60 MONTHS) AFTER EVAR.
 Procedural up  Procedural
 until 30 days > 30 days
Micro-embolism (‘trash’ foot) 10 1
Renal-artheroembolism, renal infarction 0 0
Gut ischaemia 2 0
Groin haematoma (required local intervention) 6 0
Femoral artery pseudo-aneurysm 1 0
Seroma groin wound 1 1
Superficial groin infection (diabetes) 1 0
Superficial groin infection (non diabetic) 1 0
UTI 2 0
Brachial artery puncture site haematoma 2 0
Early graft infection 1 0
Iliac artery dissection 1 0
Graft thrombosis/occlusion 1 0
Embolectomy 6 0
Renal insufficiency 1 0
Remote complications (cardiac 
failure, infarction arrythmia, stroke) 2* 3**
Amputations 1 (pt no 16) 0
*Cardiac failure (1 patient); AV-node dissociation (1 patient)
**Cardiac failure (3 patients).
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intraprocedural deployment success rate was 99%. One 
hundred and thirty-five patients (82%) were classified as 
high risk based on the ASA classification. Only 28 (17.1 %) 
of the low-risk EVAR patients were classified as ASA I or 
II. Thirty-day outcomes in 163 patients are reflected in Table 
II. Procedural morbidity (local, technical and remote) after 
device enhancement over 60 months is reflected in Table III. 
Proximal aneurysm neck morphology, assessed according to 
spiral CT, is reflected in Table IV. Device configuration 
and deployment in relation to the renal arteries is given in 
Table V. Anatomico-pathological variations and examples 
of aortic morphology affecting the region of the aneurysm 
neck (‘hostile neck’) are reflected in Fig. 1. Mortality and 
endoleak statistics are reflected in Tables VI to X.
Remote and thrombo-embolic morbidity
Peri-operative systemic complications (day 30) were record-
ed in 28 patients after EVAR. Complications that were 
detected in 28/163 (17.1%) in this study period correlated 
strongly with the severity of ASA class and combinations of 
co-morbidities (Tables I to III). Wound/access-site complica-
tions occurred in 11/163 (6.7%) but all underwent resolu-
tion. Other important complications included urinary tract 
infection (1), anaemia (1), cholecystitis (1), cardiac arrest 
(1), aneurysm rupture (1), and pyrexia (1) (see Table 
III). Both patients with the cardiac arrest and aneurysm 
rupture survived. In the latter condition, successful surgical 
conversion was affected. Thromboembolic complications, 
TABLE V. DEVICE CONFIGURATION AND STENT DEPLOYMENT 
IN RELATION TO THE RENAL ARTERY OSTIA.
Device configuration  n = 163
Bifurcation  Modular (AneuRx® and Talent®): 101  62.1%
  One piece (Endologix): 62 37.8%
Infrarenal stent graft                              163 100%
TABLE VII. STATISTICS OF ENDOLEAKS AND MAJOR CONVERSIONS 
IN 163 PATIENTS UNDERGOING EVAR.
Endoleak profile Number (%)
Total number of aortic stents (EVAR)  163
Procedural endoleaks  39 (23.9)
Endoleaks detected at 30 days  2 (1.2)
Endoleaks detected after 30 days  6 (3.6)
Persisting endoleaks  2 (1.2)
Conversion to open surgery 1 (0.6)
TABLE VIII. TOTAL ENDOLEAK RATES AND LOCATIONS AFTER EVAR 
(PROCEDURAL + LATE: BEFORE EXCLUSION).
 AneuRx® Talent® Endologix® Vanguard®
Total patients done 47 49 62 3
No endoleak 30 35 47 1
Type I 15 13 11 2
Type II 1 1 3 0
Type III 0 0 0 0
Type IV 0 0 0 0
Indeterminate 1* 0 1** 0
Total endoleaks 17 14 15 2
*Dissecting AAA, threatening rupture, excluded (patient 25)
**Rupture, patient died (patient 109).
TABLE IX. ENDOLEAK RATES AND LOCATIONS AFTER EVAR
(AFTER EXCLUSION = PERSISTING).
 AneuRx® Talent® Endologix® Vanguard®
Total patients done 47 49 62 3
No persisting endoleak 46 49 61 3
Type I 1* 0 1** 0
Type II 0 0 0 0
Type III 0 0 0 0
Type IV 0 0 0 0
Indeterminate 0 0 0 0
Total endoleak 1 0 1 0
*Patient 37: excluded at 3 months, continues at 16 months
**Patient 160: Not yet seen in follow-up.
TABLE X. PERI-OPERATIVE MORTALITY/PATIENT 
DEMOGRAPHICS AND CO-MORBIDITIES.
 Age at stenting    AAA 
 (years)    procedure 
Sex (Mean: 71.6) Co-morbidity ASA class Cause of death related
Male 58 IHD IV Cardiac/ Yes
    renal failure 
Male 75 COPD, HT  IV Multi-organ Yes 
     failure Yes 
Female 75 ICMP, HT, IV Multi-organ Yes
  COAD, AF  failure Yes
Male 73 Liver/renal V Multi-organ Yes
  failure  failure Yes
Female 77 HT, IHD, V  Renal failure  Yes
  ruptured AAA
TABLE VI. MORTALITY STATISTICS AFTER EVAR 
IN THE CURRENT STUDY.*
Variable Patients (%)
Total mortality  42 (25.7)
Intra-operative mortality     2 (1.2)
  Aneurysm related  1 (0.6)
Peri-operative mortality    5 (3.0)
  Aneurysm related  1 (0.6)
Late mortality 35 (21.4)
  Aneurysm related 1 (0.6)
*Follow-up (median 28.3 months: range 1–69 months). Five patients were lost to follow-up 
(3.1%).
TABLE IV. AAA NECK MORPHOLOGY (SPIRAL CT).
Variable Percentage 
Neck angulation > 45° n = 18 (10.9%)
Neck angulation = 45 ° n = 15 (9.1%)
Short necks* < 12 mm  n = 18 (10.9%); range (2−12 mm)
Neck length** < 20 mm n = 22 (13.4%); range (13−20 mm)
*Mean 8.6 mm (n = 11 > 10 mm: 60%)
**Mean 16.6 mm (n ≥ 15 mm: 95%)
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corrective interventions and outcomes after EVAR are 
reflected in Table XI. Acute peripheral thrombosis/embolism 
occurred in 10 patients in the 30-day period after EVAR 
(6%). Primary stent patency rate at 30 days was 97% 
(158 stents). Complications included superficial femoral 
artery (SFA) occlusion, trashing, iliac occlusion, and stent 
thrombosis (1). In 10 patients, resolution was affected 
by secondary transcatheter interventions, embolectomy, 
thrombolysis, percutaneous transluminal angioplasty (PTA) 
and use of IIb−IIIa platelet inhibitors. In 9/10 patients 
(90%) effective limb salvage by the endovascular route was 
achieved. One (1/163, 0.6%) patient had a failed primary 
vascular salvage operation due to a progressive thrombotic 
state (‘white clot’) and underwent proximal amputation 
(with underlying PVD and retinitis pigmentosa). Suspected 
pathology was a presensitised heparin thrombotic tendency 
and platelet abnormality. Heparin-induced thrombocytopae-
nia (HATT) type II and thrombosis could not be excluded 
due to heparin sensitisation following previous open-heart 
surgery and other diagnostic vascular interventions. There 
were insufficient circulating platelets to do accurate aggre-
gation laboratory tests. The patient was alive at 60 months 
post EVAR, but was re-admitted twice during this time for 
cardiac failure (IHD).
Secondary procedures and late mortality
Secondary interventions after engraftment (for various 
indications) were necessary in 21/163 patients (12.8%). 
Endovascular or selective surgical repair was indicated for 
femoral and iliac occlusion, pseudo-aneurysm, aneurysm 
rupture (one at one week), external iliac rupture, trashing, 
groin haematoma, seroma and distal thrombo-embolism 
Fig. 1. Illustrations showing important anatomical 
or pathological variations involving the neck region 
of the aneurysm in this series. Most configurations 
contribute to a ‘hostile’ aneurysm neck. These con-
figurations can impact negatively on stent place-
ment and selection during EVAR. (A): Renal ostia 
originating at different levels. (B): Aneurysmal dila-
tation at the neck with suprarenal extension. (C): 
Short conical neck. (D): Short neck. (E): Reversed 
conical neck. (F): Aberrant renal arteries. (G): 
Angulated neck and aberrant renal arteries. (H): 
Concomitant renal artery stenosis. (I): Juxtarenal 
aneurysm formation. (J): Juxtarenal thrombus for-
mation. (K, L, M, N, O, P): Degrees of angulation. 
(Q): Large aneurysm with intramural thrombus. 
(R, S, T): Cross-section of three aneurysm necks 
showing posterior plaque, ulceration and throm-
bus, all of which affect secure fixation of the 
proximal part of the device and may contribute 
to the development of type I or device-related 
proximal endoleaks.
TABLE XI. THIRTY-DAY THROMBO-EMBOLIC COMPLICATIONS 
AFTER EVAR*/SECONDARY INTERVENTIONS.
Patient Incident Intervention Outcome
1 Left SFA occlusion Thrombo-embolectomy Resolved
2 Profunda artery occlusion  Surgical thrombo- Proximal
 Left leg embolectomy and amputation
  profundaplasty/re-opro*
3 Vascular thrombosis Transcatheter re-opro Resolved
  thrombolysis* 
4 Femoral occlusion Reconstruction and   Resolved
   transcatheter embolectomy 
5 Left Iliac occlusion Thrombolysis and stent Resolved
6 Total occlusion left leg   Transcatheter embolectomy Resolved
 Compartment syndrome Fasciotomy Resolved
 left arm (from A-line)    
7 Threatened left foot  Transcatheter endarterectomy Resolved
 (?trash embolisation) and embolectomy left foot 
8 Stent thrombosis Fibrinolysis Resolved
9 Arterial insufficiency and  PTA to left iliac Resolved
 trashing to left foot 
10 Occlusion of lower limb  Arterial thrombectomy Resolved
 cural arteries and integrilin** 
*One late right iliac occlusion occurred but was reversed by insertion of a stent.
**11b−111a platelet inhibitors.
TABLE XII. LATE MORTALITY: CO-MORBIDITIES 
AND MORTALITY PROFILE AFTER EVAR (N = 35).
Co-morbidity status before stenting Cause of death after EVAR
Cardiac (IHD): 24 (68%)  Stroke: 3 
Cardiomyopathy: 5  Cancer: 9 (mean 14.3 months)
Respiratory failure: 9  Multi-organ failure: 3**
Diabetes mellitus: 4  Myocardial infarction: 7** (20 %) 
Stroke: 3  Pneumonia: 2
EF < 43%: 9  Cardiac failure: 2**
Arrhythmia: 4  Septicaemia: 2
Cancer: 2  Renal failure: 2
Hypertension: 16 (45 %)  Cardiomyopathy: 3**
PVD (occlusive): 10  Ruptured AAA: 1* (0.6 %)
Renal failure: 2  Bee-sting anaphylaxis: 1
Liver cirrhosis: 1  Endograft sepsis: 1 (0.6 %)
Obesity: 1  Unknown: 1
Hostile abdomen: 1 
AAA rupture: 1* 
Combinations: 28 (80 %) 
Age > 90 years: 1 
*One aneurysm-related death
** Cardiac-related deaths (13/35: 35%).
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(Table III). Late mortality statistics are reflected in
Tables VI, XI and XII. The causes of natural, non-
aneurysm related deaths, such as myocardial infarction, 
cardio myopathy, cancer and renal failure are displayed in
Table XII.
Endoleaks
Thirty-nine (23.9%) intraprocedural endoleaks (considered 
part of stent deployment and procedure) were detected 
by completion angiography: type I proximal (17); type I, 
proximal and distal (5); type I, distal (15), and type II, distal 
(2). Ninety-five per cent were successfully occluded by the 
use of proximal or distal devices, thrombin injection into 
the sac, or coil embolisation (see Table VII). One persisted 
for 12 months and there was one death due to aneurysm 
rupture. The latter patient died after surgical conversion 
and repair. Follow-up after 30 days revealed five late and 
two persisting endoleaks. The period of endoleak detection 
occurred between one and 52 months. Five were detected 
between three and 22 months. Persisting late endoleaks 
occurred in two patients (1.2%) and the cause remains 
indefinable. Procedural, 30-day and persisting endoleak 
incidence in the AneuRx® and Powerlink® groups did not 
reach statistical significance (p > 0.05). In the AneuRx® 
group, endoleaks were sealed in patients at three months 
(2), six months (1) and 50 months (1). In the Powerlink® 
group, one endoleak was sealed at four months (1), another 
one persisted at 30 days.
Endoleak statistics after EVAR are reflected in Tables 
VII and VIII. The incidence of type II endoleaks due to 
perigraft flow is reflected in Tables VIII and IX. Procedural 
and post-exclusion endoleak rates per stent are reflected 
in Tables VIII and IX. Procedural, 30-day and persisting 
incidence in the Aneurx® and Powerlink® groups did not 
reach statistical difference (p > 0.05). Endotension (post-
EVAR aneurysm enlargement) was detected in three patients 
(1.8%) in the study period. Endoleaks were undetectable 
despite investigations in these patients. Aneurysm size 
increase was 0.1, 0.7 and 31 mm, respectively. Late mortal-
ity figures appear in Table XII. Compared with our earlier 
experience, the introduction of the Powerlink® stent has 
reduced the incidence of late endoleaks, as aneurysm sac 
remodeling is better controlled.
Aneurysm sac changes after EVAR
Follow-up showed features of post-EVAR sac reduction, 
stabilisation and expansion. Average sac reduction was 0.96 
cm. In 2/163 (1.2%) there was an increase in sac size due 
to definable endoleaks. The increase in sac diameter at 
13 and 45 months was 0.5 cm and 1.2 cm, respectively. 
The average increase in sac diameter in these two patients 
was 0.85 cm. Endotension without definitive endoleak 
identification occurred in 3/163 patients (1.8%). Increases 
were 0.1, 0.7 and 3.1 cm, respectively over a mean period 
of 16.3 months (range 1−37 months). In these patients 
the average increase was 1.3 cm. One of 163 (1.8%) 
in the endotension group remained stable after careful, 
conservative follow-up. The other patients were scheduled 
for secondary interventions.
Discussion
Application and indications for EVAR as definitive treat-
ment of asymptomatic AAA in low- and high-risk cohorts 
has been documented by expert vascular interventional 
consensus.9,10,12,13,24,26,29,37,45,53 
Thirty-day outcome statistics after EVAR in the current 
study showed a low surgical conversion rate and procedural 
mortality (0.6% and 1.2%, respectively). Deployment suc-
cess in our series was achieved in 99% of patients undergo-
ing EVAR, and confirmed the results of Criado evaluating 
the application of Talent grafts.27,29 Considering the ASA rat-
ing, these results compared favourably with other studies.26,29 
Analysis of the 30-day data confirmed that endoleaks, 
and the secondary interventions needed to treat these, are 
the Achilles heal of EVAR.10,24,27,37,44,52-56 Our incidence of 
late persisting endoleaks was less than 5% and compared 
favourably with the literature. Other studies showed similar 
results.12,24,26,27,38,40,55 However, although secondary interven-
tions can resolve these issues effectively, this impacts on 
costs and possibly on reimbursement.56 
Our persisting endoleak rate at 30 days compared favour-
ably with other studies.26,27,38,55 Persisting endoleaks (1.2%) 
remain a challenging issue regarding diagnosis and treat-
ment. Regarding intraprocedural endoleak detection and 
prediction, we found intrasac, haemodynamic, monitoring 
and contrast angiography useful for detecting and occluding 
type I and II endoleaks. Contrast angiography of the sac and 
pressure measurements were obtained via a transfemoral 9-F 
pigtail catheter. This information proved useful in this study 
in determining if thrombin, coils or cuffs were indicated 
to ensure intra-operative occlusion of endoleaks. Additional 
80- to 100-mm proximal cuffs were used more liberally in 
patients with an aortic neck less than 12 mm and angulation 
40 to 55%. The Powerlink® (Endologix) stent showed 
promising features of columnar strength.26 The additional 
cuffs used in this situation (with a short, angulated neck) 
provided further strength and assisted in straightening the 
angle. Sac contrast angiograms assisted with important 
decision making in theatre regarding use of additional cuffs, 
coils, and thrombin in the treatment of perigraft flow.57,58 
Also, run-off speed of contrast assisted in identifying lumbar 
perigraft flow, thereby determining the safety and selection 
of the use of coils or thrombin to obtain effective intra-
operative endoleak occlusion.
Our secondary intervention rate of 12.8% compared 
favourably with international results.39,54-56 One patient need-
ed conversion to open surgery after one week (0.6%). 
Thirty-seven of 163 (22.6%) patients contributed to the 
late mortality. Many succumbed due to irreversible cardiac 
disease and cancer. Others have reported similar findings 
and have emphasised the impact of co-morbidities on even-
tual outcome and mortality in high-risk patients undergoing 
AAA repair.24,28
In our study, 132 of 163 patients (80.1%) were classified 
as ASA III or IV. Two patients died of aneurysm rupture 
after EVAR and confirmed the importance of life-long 
surveillance to detect aneurysm enlargement. Other studies 
confirmed our findings.37,38,55-57 Zarins, in a large series, 
confirmed that the risk of aneurysm-related death is sig-
nificantly lower following EVAR compared with the risk 
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of open surgery.24 In the AneuRx® stent-graft trial, 0.8% 
of patients experienced aneurysm rupture after EVAR.24,59 
However, EVAR using the AneuRx® device markedly 
reduced the risk of aneurysm rupture while eliminating 
the need for open aneurysm surgery in 98% of patients at 
one year, and 93% of patients at three years post EVAR.24 
The device was effective in preventing aneurysm rupture in 
99.5% of patients over a three-year period.24 They showed 
an overall patient survival rate of 93% at one year and 86% 
at three years.24 EVAR compared to open surgery renders 
comparable results.24 In Hallett’s population-based study, 
average five-year survival after open repair of large (> 5 
cm) aneurysms was only 60%, with most patients dying 
of myocardial infarction and other natural causes.7 High- 
and low-risk patients can therefore undergo EVAR with 
a lower rate of short-term systemic complications and a 
shorter length of hospital stay compared with open AAA 
repair.28 However, early functional outcomes are markedly 
different with EVAR compared with open surgery, whereas 
there is no difference in late functional outcomes between 
the two procedures.8 Despite the concern regarding the 
durability of EVAR, high-risk patients should be evaluated 
according to the Alabama Group for EVAR repair before 
committing them to open AAA repair.28
Three patients in the current study where diagnosed 
with endotension.54-60 Other workers have also described 
endovascular tension or pressure, in which AAA diameter 
does not decrease in size after EVAR.41,42,55,56 The treatment 
strategy remains controversial at present.54,58 These workers 
have provided evidence for intrasac pressure measurements 
intra-operatively in decision making regarding endoleaks.55 
We did not adopt this policy during follow-up because the 
space between the aneurysm wall and the stent graft was 
inadequate to be safely cannulated. Zarins, from Stanford 
University reported that aneurysm enlargement occurs in 
10% of patients undergoing EVAR and results in the need 
for conversion to open repair in 1.6% at three years.24,25 
Predictors of endotension include age, aneurysm size, 
endoleak, obesity and cancer.25 Our patients are still under 
observation and three are scheduled for secondary interven-
tions. 
We were unable to comment on post-stent aortic neck 
dilatation, as routine use of follow-up spiral CT was not 
part of our follow-up protocol, due to its high cost. May et 
al. has indicated that EVAR protects against proximal neck 
enlargement.45 Selective use of spiral CT was only consid-
ered in patients showing a sudden increase in aneurysm 
size on duplex-doppler assessment. Linear regression was 
not observed in our Powerlink® (Endologix) stent recipients. 
Freedom from rupture was 98% at 30 days in the current 
series and compared favourably with other studies.24,25 
Regarding intraprocedural endoleaks, we accept that type I 
endoleaks represent a technical failure of EVAR and should 
be corrected promptly by endovascular means.55 This is our 
policy when performing EVAR. We experienced a high 
degree of exclusion using extensions/cuffs in our study.55 
On the other hand, type II endoleaks are generally cited 
to be benign enough to possibly warrant a short period of 
observation.24,38,40,55,56 We were unable to substantiate these 
findings from our study.
The question of whether successful EVAR treatment 
should be based on a reduction of AAA size over time 
remains unanswered and controversial.57 A reduction or 
stabilisation in sac size over time after EVAR is reassuring.57 
Reduction in sac size usually means the pressure inside 
the sac is reduced.55 Endotension, with significant increase 
in sac size after EVAR, mandates further investigation to 
detect a missed type I endoleak that could cause rupture.54 
Of importance is that some authors have reported sac 
expansion and rupture even in the absence of endoleaks.58 
Sac regression after EVAR varies from study to study. 
Zarins demonstrated that only 14 to 25% of Aneurx® patients 
had sac regression of more than 5 mm during a one- to 
three-year follow-up.59 Other groups report variable sac 
shrinkages in mid-term follow-up varying from 27 to 60%.59 
Malina et al. proposed that most sac regression occurred in 
the first year after EVAR, with minimal changes thereafter.60 
Others confirm that sac shrinkage is quite variable and 
depends on the graft type.57 Three of 163 (1.8%) developed 
endotension in this study and two are scheduled for second-
ary interventions.54 For FDA-approved trials, the definition 
of significant reduction in sac size was set at a minimum of 
5 mm. Further studies are needed to elucidate all responsible 
factors that contribute to sac shrinkage, stabilisation, growth 
and endotension.38 Long-term post-EVAR surveillance is 
needed to ensure permanent aneurysm exclusion.38,54-56 
This clinical study did not answer the following question: 
‘Have AAA endografts passed the clinical test?’ Currently, 
the answer is ‘no’.39 Veith and co-workers, of Montifiore 
Hospital have recommended careful selective use of EVAR 
until more definite devices have proven long-term durabil-
ity. Also, the question ‘Is EVAR of value in the good-risk 
patient compared to open conventional surgery?’ remains 
unanswered and speculative. At the moment the jury is still 
out. The justification of EVAR in the young person with 
AAA remains controversial, and more trials are needed until 
we have proven long-term results of endograft performance. 
Our policy is to refer young persons with AAA for open, 
conventional surgery. Our multidisciplinary group does 
not concur with the suggestion of Collin and Murie that 
EVAR is a failed experiment.61 These authors argue that the 
observed rupture risks of 1% per year after endovascular 
repair is not remarkably different from the natural history of 
most small aneurysms followed up without intervention.61 
Results from large trials and data from the EUROSTAR 
registry indicate that EVAR can provide substantial clinical 
benefit for the patient with AAA and that aneurysm-related 
deaths can be controlled, provided the patient is carefully 
selected for EVAR.12 We concur with these findings and 
recommendations.
Secondary intervention rate in this study was 12.8%, 
compared to the 18% reported by the EUROSTAR registry.12 
EUROSTAR predicts that the cumulative rate of freedom 
from secondary interventions at two years post EVAR is 
62%.12,56 Transabdominal, extra-anatomical, and transfemo-
ral secondary procedures may be indicated in 10 to 76% 
of patients after aortic stenting.56 Therefore surveillance is 
important to predict the necessity for maintenance interven-
tions.56 Our patients are undergoing long-term follow-up. 
The EUROSTAR registry indicates that researchers do not 
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fully appreciate the importance of long-term integrity of 
stent devices, effect of exclusion on AAA remodeling or 
devices, implications of late endoleaks, and dangers of 
endotension.
Recommendations from the literature indicate that EVAR 
is indicated in high-risk patients, those with hostile abdo-
mens, patients with anastomotic and isolated iliac aneurysms, 
and selected patients with ruptured AAA.52,62-66 Regarding 
ruptured AAA, Hinchliffe et al. have suggested that patients 
with leaking aneurysms were more likely to have larger 
aneurysms with shorter and narrower proximal necks.67 
In their study, they found that ruptured AAAs were less 
likely to be suitable for endovascular repair than their 
intact asymptomatic counterparts.67 They speculate that open 
repair is likely to remain the treatment of choice in the 
majority of patients with ruptured AAA, owing to the 
current morphological constraints of endovascular repair.67 
Our study did not address these dilemmas and therefore, 
with regard to ruptured AAA, we adopt highly selective 
inclusion criteria at present. Other workers have recently 
indicated that EVAR is a feasible treatment in the majority 
of patients with ruptured and symptomatic AAA.42,65,66 The 
association of endoleaks and late AAA rupture after EVAR 
is currently being evaluated.59,66-69
EVAR in women has been reported to present technical 
challenges and may cause more frequent late complica-
tions.70 As only 8% (13) of our EVAR study included female 
patients, our experience is too little to substantiate these 
findings.70 The calibre of the common iliac arteries in our 
study was critical to allow aneurysm exclusion with the 
Endologix device. Patients with small vessels and run-off 
were excluded from EVAR and referred for conventional 
open surgery.
Acute lower limb ischaemia after conventional aortic 
grafting for AAA may be due to embolism, ‘trashing’, 
thrombosis or technical errors.71,72 Prosthetic limb thrombosis 
is also an important cause of acute ischaemia. Embolism 
is the most common cause of ischaemic complications 
and occurs in about 10 to 15% of cases.72,73 Lord et al. 
reported an embolism incidence of 29% after 133 open 
aneurysmectomies over a four-year period.73 In a series of 
262 AAA repairs by the open route, Strom et al. reported 
an incidence of acute limb ischaemia in 10.3% of patients 
post reconstruction.71 The incidence of post-stent thrombo-
embolism in our EVAR study was 6.1% (10 patients). 
Primary stent patency rate at 30 days was 97%. In nine 
of 10 patients, limb salvage was successfully achieved 
by secondary emergency endovascular interventions, includ-
ing embolectomy, endarterectomy, thrombolysis, additional 
stents and the use of IIb−111a platelet inhibtors. Incidence 
of proximal amputation in our series was 0.6% (one 
patient). This occurred in a high-risk patient with underlying 
symptomatic PVD (occluded SFA) and ischaemic heart 
disease, and retinitis pigmentosa (RP) after insertion of a 
Talent® stent. Coagulopathy and hyperviscosity syndrome 
predisposes to early graft or distal vessel thrombosis.74-76 
Underlying causes of vessel occlusion include thrombocy-
topaenia, antithrombin deficiency, abnormal RBC fragility, 
or heparin-induced platelet aggregation.74-76 Some of those 
underlying factors are present in patients with RP and may 
explain the reason for failed vascular limb-salvage interven-
tion in our series for acute limb ischaemia.74-76 Additional 
factors in RP that may predispose to arterial thrombosis 
include thrombocytopaenia, abnormal platelet taurine 
metabolism, disturbed erythrocyte osmotic fragility and 
hyperlipidaemia.74-77 These patients with the underlying 
metabolic syndrome and hyperviscosity are at increased risk 
for unpredictable arterial thrombosis after aneurysm repair 
in the early and late post-operative period. Lower-extremity 
amputation secondary to heparin-associated thrombocyto-
paenia (HATT) due to thrombosis, and limb ischaemia may 
occur in any patient exposed or previously presensitised to 
heparin.77-79 Re-exposure to heparin in patients displaying 
type II HATT results in a rapid decline in platelets within 
minutes to hours.
Overcoming the problem of an unfavourable or subopti-
mal proximal aneurysm neck morphology as depicted in 
Fig. 1 is challenging − most units refer the patient for 
conventional surgery in such cases. Recent studies show 
that suprarenal endograft fixation is desirable for a more 
secure form of proximal fixation and to increase the number 
of patients eligible for EVAR.80,81 Our study did not address 
this application. However, we are of the opinion that the 
application of the Powerlink® stent allows better intra-
operative control of patients with angulated aneurysm 
necks. Our impression is that the introduction of the newer-
generation stents has impacted more favourably on our 
initial experience. Operation times seldom exceed one hour, 
a lower incidence of endoleaks are detectable, stent migra-
tion is reduced, and negative aneurysm sac remodeling after 
EVAR is reduced.
In many high-risk patients, EVAR is considered an 
end-of-life intervention. Some elderly patients with AAA 
and severe co-morbidities are not fit for EVAR or open con-
ventional surgery. Our multidisciplinary group agrees with 
the sentiments of Jones et al. from the Center for Medical 
Ethics and Health Policy, Baylor College of Medicine, ‘that 
once a futility state is realized, it is unethical to apply 
surgical skills uselessly’.82 Our group would not consider 
a 79-year-old female with advanced Alzeimer’s disease, 
a symptomatic 10-cm AAA and increasing back pain, as 
suitable for EVAR. Our approach would follow the same 
recommendations as Jones et al.: meet with the immediate 
family or friends to discuss the patient’s values, beliefs and 
preferences, and outcomes, and select a clinical intervention 
accordingly.82 This may entail withholding futile and heroic 
surgery and allow to the patient to die a natural death.82
Conclusions
Regarding the primary goals of AAA exclusion, this study 
supports the hypothesis that it is possible to prevent rupture 
and aneurysm-related death by EVAR in more than 90% of 
patients in the intermediate to mid-term.9,12,13,18,24,26,44 Due to 
severe co-morbidities and distorted anatomy affecting safe 
stent fixation and access, EVAR was not feasible in 21% 
of referrals. Successful device deployment was possible in 
more than 90% of selected aneurysm recipients, rendering 
a 30-day procedural mortality rate of 1.2% and late persist-
ing endoleak incidence of 1.2%. Twenty-four per cent of 
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patients after EVAR needed secondary endovascular inter-
ventions. The EUROSTAR registry demonstrated evidence 
and outcome for the application of EVAR in patients 
with AAA.12 Life-long post-EVAR surveillance is needed 
to detect late persisting endoleaks and prevent aneurysm 
rupture.83-85 EVAR is still undergoing a process of technologi-
cal evolution with improving mid- to long-term results.24 A 
high attrition rate in high-risk aged patients with AAA can 
be expected after EVAR due to natural deaths from cardiac 
causes and cancer.4 This also applies to patients undergoing 
AAA repair by the conventional open surgical route.7-10
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Appendix 1.
Institutions and investigators participating in this 
 ongoing EVAR study included the following:
D.F. du Toit, Faculty of Health Sciences, University
of Stellenbosch; C.F. Pretorius, Vergelegen Medi-
Clinic; H. Louwrens, J.A. Saaiman, W. Smit,
L. MacGregor, D. van der Merwe, H van Rooyen,
G. Warren, S. Weideman, Panorama Medi-Clinic;
R. de Beer, Louis Leipoldt Hospital; R. Allen, 
The Sanger Clinic, Charlotte, North Carolina, U.S.A.; 
J. Potgieter, C. Treunicht, M. de Kock, N1 City 
Hospital, Goodwood; J. Stofberg, H. Prins, Louis 
Leipoldt Hospital; C. Dreyer, Christian Barnard 
Memorial Hospital; D. du Toit, Tygerberg Hospital;
J. Klompje, Paarl Medi-Clinic; G. Morrison, Worcester 
Medi-Clinic; D. Notling, Stellenbosch Medi-Clinic;
E. Swanepoel, Durbanville Medi-Clinic.
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